Cd10 clone 56c6

Manufactured by Leica

Sourced in United Kingdom, Denmark, Germany

The CD10 (clone 56C6) is a laboratory equipment product. It is used for the detection and analysis of CD10 antigen expression in various cell types. The core function of this product is to provide a tool for researchers and clinicians to investigate CD10 expression patterns.

Automatically generated - may contain errors

Lab products found in correlation

Bcl6 clone ln22, by Leica (5 mentions) Cd20 clone l26, by Agilent Technologies (5 mentions) Ventana benchmark xt, by Roche (4 mentions) Ki 67 clone mib 1, by Agilent Technologies (4 mentions) Bcl2 clone 124, by Agilent Technologies (3 mentions) Myc clone ep121, by Cell Marque (3 mentions) Mum1 clone ma695, by Leica (3 mentions) Bond max autostainer, by Leica (3 mentions) Cd3 clone ln10, by Leica (3 mentions) Cd3 clone 2gv6, by Roche (2 mentions) Pd 1 clone mrq 22, by Cell Marque (2 mentions) Bond ready to use ish eber probe, by Leica (2 mentions) Mum1 clone mum1p, by Agilent Technologies (2 mentions) Cd79a clone 1.10e 04, by Leica (2 mentions) Pax5 clone r1, by Agilent Technologies (2 mentions) Bcl6 clone p1f6, by Agilent Technologies (2 mentions) Cd43 clone df t1, by Agilent Technologies (2 mentions) Ventana benchmark xt system, by Roche (1 mentions) Bond max, by Leica (1 mentions) Cd20 clone l26, by Leica (1 mentions)

Spelling variants of this product

CD10 (56C6, (15 citations) Anti‐CD10 (Clone 56C6; (2 citations)

15 protocols using cd10 clone 56c6

Immunohistochemical Profiling of Lymphoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemistry (IHC) was performed using antibodies against MYC (clone EP121, Cell Marque, Rocklin, CA, USA), BCL2 (clone 124, DAKO, Carpinteria, CA, USA), BCL6 (clone LN22, Novocastra, Newcastle, United Kingdom), CD10 (clone 56C6, Novocastra), and MUM1 (clone Ma695, Novocastra). IHC staining was performed using the Ventana Benchmark XT system (Ventana Medical Systems, Tucson, AZ, USA) or a Bond-Max automated immunostainer (Leica Microsystems, Melbourne, Australia). Cell of origin was assessed according to the Hans criteria [11 (link)]. IHC score was determined to be the percentage of tumor cells with robust immunostaining evaluated by 10 % increments. Cutoff values (i.e. IHC scores) of ≥40 % for MYC, ≥30 and ≥60 % for BCL2 and ≥50 % for BCL6 were determined to have discriminant prognostic power based on the receiver operator characteristic (ROC) curves and were thus used for classifying cases into MYC-, BCL2- or BCL6-negative and-positive groups.

Kim S., Nam S.J., Kwon D., Kim H., Lee E., Kim T.M., Heo D.S., Park S.H., Kim C.W, & Jeon Y.K. (2016). MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system. BMC Cancer, 16, 363.

+ Open protocol

+ Expand

Immunohistochemical Profiling of Follicular Lymphoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

All cases were reviewed, and based on the revised 4th edition of the World Health Organization classification criteria, patients with testicular FL, duodenal-type FL, and pediatric-type FL were excluded [2 ]. The following pathological parameters were recorded: histologic grade (grades 1–2, grade 3A, and grade 3B), histologic pattern (follicular, follicular and diffuse, and diffuse), and immunophenotype (expression of BCL2, BCL6, CD10, or Ki-67). Immunohistochemical (IHC) staining was performed on whole slides using a fully automated IHC assay on a Ventana BenchMark XT Autostainer (Ventana Medical Systems, Woonsocket, RI, USA). Antibodies specific for the following markers were used: CD3 (clone PS1, mouse mAb, Novocastra, Newcastleupon-Tyne, UK), CD5 (clone 4C7, mouse mAb, Novocastra), CD20 (clone L26, mouse mAb, Novocastra), Ki-67 (mouse mAb, Dako, Glostrup, Denmark), CD10 (clone 56C6, mouse mAb, Novocastra), CD21 (clone 2G9, mouse mAb, Novocastra), BCL2 (clone E17, rabbit mAb, Cell Marque, Rocklin, CA, USA), and BCL6 (clone GI191E/A8, mouse mAb, Cell Marque). Immunostained slides from 239 FL cases were reviewed, and immunopositivity was defined as protein expression by ≥30% of the tumor cells [15 (link)-18 (link)]. Ki-67 proliferation index (PI) was assessed manually in neoplastic follicles, and a Ki-67 PI ≥ 30% was deemed as high expression [19 (link)-23 (link)].

Kim M., Hwang H.S., Cho H., Yoon D.H., Suh C., Park C.S., Go H, & Huh J. (2021). Upward trend in follicular lymphoma among the Korean population: 10-year experience at a large tertiary institution. Journal of Pathology and Translational Medicine, 55(5), 330-337.

+ Open protocol

+ Expand

Immunohistochemical and FISH Analysis of DLBCL

Check if the same lab product or an alternative is used in the 5 most similar protocols

IHC was prospectively performed on the routine diagnostic basis using representative whole formalin-fixed paraffin-embedded (FFPE) tissue sections and antibodies against CD3 (clone 2GV6; Ventana Medical Systems, Tucson, AZ, USA), CD20 (clone L26; DAKO, Carpinteria, CA, USA), BCL2 (clone 124; DAKO, Carpinteria, CA, USA), BCL6 (clone LN22; Novocastra, Newcastle, UK), CD10 (clone 56C6; Novocastra), MUM1 (clone Ma695; Novocastra), MYC (clone EP121; Cell Marque, Rocklin, CA, USA), and Ki-67 (clone MIB-1; DAKO). Staining was performed using a Ventana Benchmark XT (Ventana Medical Systems) or a Bond-Max autostainer (Leica Microsystems, Melbourne, Australia). COO was determined using the IHC-based Hans algorithm as previously described [29 (link)]. DE status was defined as the co-expression of MYC (in ≥40% of tumor cells) and BCL2 (in ≥70% of tumor cells) as previously described [12 (link)]. TMA was constructed using the FFPE tissue blocks from 50 selected cases with DLBCL, and we performed MYC, BCL2, BCL6 FISH on the TMA. FISH was performed using Vysis LSI BCL2 Dual Color Break Apart Rearrangement Probe (Vysis, Downers Grove, IL, USA), Vysis LSI BCL6 Dual Color Break Apart Rearrangement Probe (Vysis), and Vysis LSI MYC Dual Color Break Apart Rearrangement Probe (Vysis)).

Han B., Kim S., Koh J., Yim J., Lee C., Heo D.S., Kim T.M., Paik J.H, & Jeon Y.K. (2020). Immunophenotypic Landscape and Prognosis of Diffuse Large B-Cell Lymphoma with MYC/BCL2 Double Expression: An Analysis of A Prospectively Immunoprofiled Cohort. Cancers, 12(11), 3305.

+ Open protocol

+ Expand

Immunohistochemical Analysis of DLBCL

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemical analysis was performed for CD10 (clone 56C6; Novocastra), BCL6 (clone LN22; Novocastra), and MUM1 (clone MUMp1; DAKO) using a streptavidin-biotin complex technique and 4-um thick unstained slides. The cell of origin classification was based on the Hans algorithm [24 (link)]. Cell of origin was identified in 49 of the 81 HBsAg-positive DLBCL patients. To exclude the impact of occult HBV infection, cell of origin was also identified in 93 of the 264 DLBCL patients who were negative for both HBsAg and HBcAb.

Deng L., Song Y., Young K.H., Hu S., Ding N., Song W., Li X., Shi Y., Huang H., Liu W., Zheng W., Wang X., Xie Y., Lin N., Tu M., Ping L., Ying Z., Zhang C., Sun Y, & Zhu J. (2015). Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin. Oncotarget, 6(28), 25061-25073.

+ Open protocol

+ Expand

Immunohistochemical Profiling of Tfh Markers in PTCL-NOS

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemical (IHC) studies were performed using FFPE with the following antibodies: CD10 (clone 56C6, Novocastra, Newcastle, UK), BCL6 (clone LN22, Novocastra), PD-1 (clone MRQ-22, Cell Marque, Rocklin, CA, USA), CXCR5 (clone 51505, R&D Systems, Minneapolis, MN, USA), ICOS (clone EPR20560, Abcam, Cambridge, UK), TCF1 (C63D9, Cell Signaling Technology, Danvers, MA, USA), T-bet/TBX21 (4B10, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), CXCR3 (clone CD183, BD PharMingen, Heidelberg, Germany), GATA3 (Clone L50–823, Biocare Medical, Concord, CA, USA), CCR4 (polyclonal, catalog #: HPA031613, Sigma-Aldrich, St. Louis, MO, USA). Immunostaining was performed using a Ventana Benchmark XT (Ventana Medical Systems, Tucson, AZ, USA) or a Bond-Max Autostainer (Leica Microsystems, Melbourne, Australia). The expression of Tfh markers (CD10, BCL6, PD-1, CXCR5, and ICOS) in CD3+ cells were considered positive if they were above 10% [25 (link)]. According to the IHC subclassification algorithm in PTCL-NOS [20 (link)], TBX21 and CXCR3 were considered positive above a 20% threshold, and GATA3 and CCR4 were considered positive beyond a 50% cutoff of CD3+ cells. The proportion of positive cells for TCF1 in the total CD3+ cells were graded as 0 (0%–10%), 1+ (10%–30%), 2+ (30%–50%), and 3+ (> 50%).

Han B., Lim S., Yim J., Song Y.K., Koh J., Kim S., Lee C., Kim Y.A, & Jeon Y.K. (2024). Clinicopathological implications of immunohistochemical expression of TBX21, CXCR3, GATA3, CCR4, and TCF1 in nodal follicular helper T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified. Journal of Pathology and Translational Medicine, 58(2), 59-71.

+ Open protocol

+ Expand

Immunohistochemical Profiling of B-cell Lymphomas

Check if the same lab product or an alternative is used in the 5 most similar protocols

IHC was performed using antibodies against CD3 (clone 2GV6; Ventana Medical Systems, Tucson, AZ), CD20 (clone L26; DAKO, Carpinteria, CA), BCL2 (clone 124; DAKO), BCL6 (clone LN22; Novocastra, Newcastle, UK), CD10 (clone 56C6; Novocastra), MUM1 (clone Ma695; Novocastra), MYC (clone EP121; Cell Marque, Rocklin, CA), Ki-67 (MIB-1; Ventana Medical Systems), PD-1 (clone MRQ-22; Cell Marque), IgD (clone DRN1C; Novocastra), and FOXP1 (clone SP133; Cell Marque) on representative whole FFPE tissue sections. Epstein-Barr virus in situ hybridization was performed using the Bond Ready-to-Use ISH EBER probe (Leica Biosystems, Newcastle, UK) or the INFORM EBER probe (Ventana Medical Systems). Immunostaining was performed using Ventana Benchmark XT (Ventana Medical Systems) or Bond-Max autostainer (Leica Microsystems, Melbourne, Australia) according to the manufacturer’s protocol.
B-cell monoclonality was detected using the IdentiClone IGH Gene Clonality Assay (Invivoscribe Technologies Inc., San Diego, CA).

Lim S., Lim K.Y., Koh J., Bae J.M., Yun H., Lee C., Kim Y.A., Paik J.H, & Jeon Y.K. (2022). Pediatric-Type Indolent B-Cell Lymphomas With Overlapping Clinical, Pathologic, and Genetic Features. The American Journal of Surgical Pathology, 46(10), 1397-1406.

+ Open protocol

+ Expand

Immunohistochemical Analysis of Nail Matrix

Check if the same lab product or an alternative is used in the 5 most similar protocols

Samples were sectioned longitudinally parallel to the long axis of the nail plate or transversally. Hematoxylin- and eosin-(H&E) stained slides of the specimens were reviewed to determine the most comprehensive section. Immunohistochemical staining was done using a monoclonal antibody against CD10 (clone 56C6; Novocastra, Newcastle, UK), SPINK6 (ab110830; Abcam, Cambridge, UK), β-catenin (14; Cell Marque, CA, USA) or LEF1 (ab137872; Abcam, Cambridge, UK). For IHC, tissue sections were deparaffinized with xylene and rehydrated with ethanol. To block endogenous peroxidase in the tissue sections, the slides were treated with hydrogen peroxide in methanol. Sections were incubated in a blocking solution (Protein block, DAKO) to prevent nonspecific antibody binding. The sections were then incubated with primary antibody for a few hours at room temperature in a humid chamber. The slides were washed in phosphate buffered saline, followed by antigen detection using DAKO EnVision System and diaminobenzidine or Fast Red for visualization. The slides were counterstained with hematoxylin solution.

Kim H.J., Shim J.H., Park J.H., Shin H.T., Shim J.S., Jang K.T., Park W.Y., Lee K.H., Kwon E.J., Jang H.S., Yang H., Lee J.H., Yang J.M, & Lee D. (2021). Single-cell RNA sequencing of human nail unit defines RSPO4 onychofibroblasts and SPINK6 nail epithelium. Communications Biology, 4, 692.

+ Open protocol

+ Expand

Comprehensive Immunohistochemical Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemistry was performed on 2 μm-thick dewaxed sections after antigen retrieval (PTLink at 92 °C for 5 min in EnVision Flex Target Retrieval Solution High pH) using a Dako AutoStainer Link48 (Dako Agilent, Glostrup, Denmark). Sections were stained for: GATA3 (clone EPR16651 Abcam), TBX21/T-bet (clone 4B10, 4BD Pharmingen), CD2 (clone AB75, Leica), CD3 (polyclonal, Agilent), CD4 (clone 1F6, Leica), CD5 (clone 54/F6, Agilent), CD7 (clone 580, Leica), CD8 (clone 144B, Agilent), CD30 (clone Ber-H2, Agilent), PD1 (clone NAT1, CNIO), BCL6 (clone PG-B6P, Agilent), CD10 (clone 56C6, Leica), CXCL13 (polyclonal, R&D Systems), TIA1 (clone 249, Immunotech), Granzyme B (clone 11F1, Leica), Perforin (clone 5B10, Bio Optical), CD20 (clone L26, Agilent), PAX5 (clone DAK-PAX5, Agilent), CD21 (clone 1F8, Agilent), and Ki-67 (clone Mib1, Agilent). Alkaline phosphatase anti-alkaline phosphatase was applied for antibody detection.
Immunohistochemical results were evaluated with a semiquantitative approach (H-score, range 0–300) multiplying the percentage of positive cells (0–100%) and the intensity of staining (0–3+).

Laginestra M.A., Cascione L., Motta G., Fuligni F., Agostinelli C., Rossi M., Sapienza M.R., Righi S., Broccoli A., Indio V., Melle F., Tabanelli V., Calleri A., Novero D., Facchetti F., Inghirami G., Sabattini E., Bertoni F, & Pileri S.A. (2019). Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. Modern Pathology, 33(2), 179-187.

+ Open protocol

+ Expand

Immunohistochemical Analysis of INADA Tumor Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols

Expression of the PD-L1 protein and cell differentiation markers in tumors from 54 patients with INADA was detected by immunohistochemistry (IHC). FFPE tissue sections with a thickness of 4 µm were prepared and subjected to IHC with an automated Bond-III slide stainer (Leica Biosystems, Wetzlar, Germany) in accordance with the manufacturer's protocol using mouse anti-human monoclonal antibodies against MUC6 (clone CLH5; 1:100; Novus, America), MUC5AC (clone CLH2; 1:100; DAKO, Denmark), MUC2 (clone CCP58; 1:100; DAKO, Denmark), CD10 (clone 56C6; 1:70; Leica, Germany), and PD-L1 (clone SP263; rabbit monoclonal primary anti-PD-L1 antibody, prediluted, Ventana Medical Systems, Tucson, AZ). For PD-L1, reactivity was evaluated separately for cancer cells and in ltrating immune cells. Cases with ≥ 1% of cells (membrane staining) being stained were considered to be PD-L1 positive (Pollack et al. 2021) (link). For mucin histochemical staining, cytoplasmic reactivity was determined to be a positive outcome for MUC6, MUC5AC and MUC2, and luminal membranous reactivity was determined to be a positive result for CD10. Gastric phenotypic markers (MUC6 and MUC5AC) and intestinal phenotypic markers (MUC2 and CD10) were evaluated as positive when immunoreactivity was observed in ≥ 10% of tumor cells (Yoshida et

Yang G., Tanaka T., Kinugasa H., Kanzaki H., Chen M.X., Ichimura K., Nakagawa M., Jin Z.S., Zheng R.Y, & Yoshino T. (2022). Microsatellite Instability Analysis and Its Prognostic Value in Invasive Nonampullary Duodenal Adenocarcinoma. Oncology, 100(5).

+ Open protocol

+ Expand

Cytopathological Examination of Vitreous Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cell block preparations were performed as follows. Vitreous perfusion fluid was centrifuged at 3,000 rpm for 3 min and the supernatant was discarded. The dry pellet was fixed in 10% neutral buffered formalin overnight, and then the samples were processed for paraffin embedding and sectioning as usual.
For cytopathological examination, we examined cellularity, background appearance, cell types, and cell atypia. The extents of necrosis, neutrophils, histiocytes, small lymphocytes and atypical lymphocytes were scored as absent (-), mild (+), moderate (++) or marked (+++).
In lymphoma cases or possible lymphoma cases, immunocytochemical staining was performed using antibodies against CD3 (clone LN10, Leica, RTU), CD5 (Clone 4C7, Leica, RTU), CD20 (clone MJ1, Leica, RTU), CD10 (clone 56C6, Leica, RTU), CD56 (clone CD564, Leica, RTU), Bcl-2 (Clone bcl-2/100/D5, Leica, RTU), Bcl-6 (clone LN22, Leica, RTU), MUM-1 9 (clone EAU32, Leica, RTU) and Granzyme B (clone GrB-7, MONOSAN, 1:50). For in situ hybridization, a Bond™ Ready-to-Use ISH EBER Probe (Leica, Catalog No: PB0589probe) was used. 10

Kanno-Okada H., Takakuwa E., Tagawa Y., Kase S., Hatanaka K.C., Hatanaka Y., Namba K., Mitsuhashi T, & Matsuno Y. (2017). Cytopathologic findings of cell block materials from the vitreous: Diagnostic distinction between intraocular lymphoma and non-lymphomatous diseases. Pathology international, 67(7).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!